The annual American Society of Clinical Oncology Conference kicks off Friday, June 1, 2018.
Every year, thousands of healthcare professionals, scientists, and investors assemble in Chicago to hear about the latest scientific breakthroughs redefining cancer care. Over the course of this five-day conference, hundreds of companies -- including Celgene (NASDAQ: CELG) , Gilead Sciences (NASDAQ: GILD) , and Loxo Oncology (NASDAQ: LOXO) -- will be providing much-anticipated pipeline updates and plenty of market-moving news.
Not in Chicago? No worries! The Motley Fool's healthcare team has got you covered with all the latest headlines, announcements, and analysis. Be sure to check back on this page for updates!
- Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
- Does a Blue Ribbon Make This Biotech Stock a Buy Now?
- Read This Before You Buy Immuno-Oncology Stocks
10 stocks we like better than Loxo Oncology
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Loxo Oncology wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
Shannon Jones has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
